No registrations found.
ID
Source
Brief title
Health condition
Pancreatic cancer
Sponsors and support
Intervention
Outcome measures
Primary outcome
Ct-DNA levels in pancreatic juice and serum in relation to (progression-free) survival.
Secondary outcome
Ct-DNA levels in pancreatic juice and serum
CINdex in pancreatic juice and serum
The cellular composition of pancreatic juice (Number of cancer cells, Clonality of the cancer cells, Intracellular (single-cell) mutations, capability to grow organoids)
Molecular composition of pancreatic juice (Levels of pro- and anti-inflammatory molecules, inhibitory and activating immune cells, molecules related to fibrosis)
(Progression free) survival (assessed after 12 and 18 months)
Tumour size
Presence of metastases
Background summary
The incidence of pancreatic cancer (PC) in the Netherlands is low, yet the prognosis is dismal. In 2030, PC is even expected to be the number one cause of cancer related death, worldwide. At present, PC diagnosis is based on imaging, yet the development of biomarkers is needed, not only to enable timely detection, but also to allow personalised care and early prediction of treatment response. Individual biomarkers seem to have a limited predictive value. A broad approach is needed, investigating different molecular markers in different biomaterials (serum and pancreatic juice) to develop a combination of tests that will improve PC survival. We expect to detect cellular and extra-cellular components of the tumour in pancreatic juice and serum (ct-DNA, cytokines, fibrotic mediators), serving as promising targets for biomarker detection.
Study objective
We hypothesize to find an association between these ct-DNA levels in pancreatic juice and blood and (progression-free) survival.
Study design
Pancreatic juice and serum collections will be performed during EUS. Further disease and survival characteristics will be collected up to 2 year after inclusion.
Intervention
No interventions
Inclusion criteria
All patients with (suspected) pancreatic cancer that undergo an EUS either as part of a diagnostic process or for fiducial placement prior to treatment.
Exclusion criteria
A potential subject that is younger than 18 years old will be excluded from participation in this study.
Design
Recruitment
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL7383 |
| NTR-old | NTR7591 |
| CCMO | NL64724.078.18 |
| OMON | NL-OMON54838 |